RGNX - REGENXBIO Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.44B
Enterprise Value 31.06B
Trailing P/E N/A
Forward P/E 160.05
PEG Ratio (5 yr expected) 1-10.02
Price/Sales (ttm)26.19
Price/Book (mrq)2.90
Enterprise Value/Revenue 319.25
Enterprise Value/EBITDA 6-12.07

Trading Information

Stock Price History

Beta (3Y Monthly) 1.42
52-Week Change 3-34.23%
S&P500 52-Week Change 38.02%
52 Week High 373.81
52 Week Low 330.38
50-Day Moving Average 336.36
200-Day Moving Average 344.52

Share Statistics

Avg Vol (3 month) 3585.63k
Avg Vol (10 day) 3624.49k
Shares Outstanding 536.81M
Float 28.79M
% Held by Insiders 115.70%
% Held by Institutions 183.65%
Shares Short (Sep. 30, 2019) 44.17M
Short Ratio (Sep. 30, 2019) 46.66
Short % of Float (Sep. 30, 2019) 414.75%
Short % of Shares Outstanding (Sep. 30, 2019) 411.32%
Shares Short (prior month Aug. 30, 2019) 43.22M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 31, 2018
Most Recent Quarter (mrq)Jun. 30, 2019

Profitability

Profit Margin -88.57%
Operating Margin (ttm)-169.66%

Management Effectiveness

Return on Assets (ttm)-13.45%
Return on Equity (ttm)-11.97%

Income Statement

Revenue (ttm)54.85M
Revenue Per Share (ttm)1.53
Quarterly Revenue Growth (yoy)-80.30%
Gross Profit (ttm)124.99M
EBITDA -87.44M
Net Income Avi to Common (ttm)-48.58M
Diluted EPS (ttm)-1.36
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)341.5M
Total Cash Per Share (mrq)9.28
Total Debt (mrq)6.93M
Total Debt/Equity (mrq)1.40
Current Ratio (mrq)14.58
Book Value Per Share (mrq)13.46

Cash Flow Statement

Operating Cash Flow (ttm)-76.74M
Levered Free Cash Flow (ttm)-52.32M